Lung Cancer

Can Quality of Life Assessments Predict PFS, OS Across Cancer Types?

By

Julia Faith Sklar

Publish Date November 3, 2021

Recent studies showed associations between quality of life scores and survival in lung and prostate cancer as well as renal cell carcinoma.

First-Line Immunotherapy Continues to Best Chemo in Malignant Pleural Mesothelioma

By

Alan P. Lyss, MD

Publish Date October 29, 2021

Data suggest nivolumab plus ipilimumab provides a long-term survival benefit in patients with unresectable malignant pleural mesothelioma.

How COVID-19 Affected Management of Lung Nodule Programs

By

Rosemarie A. Tucci, MSN, RN, AOCN®

Publish Date September 13, 2021

Dramatic changes made to lung nodule programs due to COVID-19 included changes to screening criteria and follow-up protocols, plus a whole new group of patients.

Extending Dosing Interval May Not Impact Safety, Efficacy of ICIs in Lung Cancer

Survival outcomes were similar for patients with an extended dosing interval and patients who received standard dosing.

Stage Shift Tied to Decreased Population Mortality in NSCLC

A stage shift from later- to earlier-stage disease during the last decade was associated with improved survival among patients with NSCLC.

Patritumab Deruxtecan Gets Breakthrough Tx Status for Metastatic EGFR-Mutated NSCLC

Patritumab deruxtecan consists of a fully human anti-HER3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.

First-Line Osimertinib: Proceed With Caution in Elderly Patients With NSCLC

The high frequency of pneumonitis “is a serious concern,” according to researchers.

Physical Manipulation Pulmonary Rehabilitation Improved Lung Function After Lobectomy for NSCLC

A randomized, controlled trial was conducted to determine if physical pulmonary rehabilitation could improve outcomes after lobectomy for patients with NSCLC.